| Name | Title | Contact Details |
|---|
Located in the heart of Amish Furniture Country two miles west of Mount Hope, Ohio, Mullet Cabinet is leading the way in custom cabinetry. Founded in 1965 on the core values of integrity, honesty and a strong work ethic that was handed down to us from our Amish Heritage, we have been creating handcrafted custom cabinetry and providing exceptional customer service for nearly 35 years
Turn One is a manufacturer of high performance power steering boxes, pumps, pulleys and accessories. We also offer rebuilding services for power steering boxes, pumps, and rack & pinion assemblies. Delivering the highest quality parts for drivers that demand the best in steering performance!
Hancock and Moore Fine Furniture
In todays environment, it has never been easier to feel left behind. Clearoute is a consulting agency with expertise in helping businesses to develop and implement customized solutions that are tailored to their specific needs and goals. You need a strategic ally who can harness brand, performance-marketing, tech & innovation, sales, and finance to deliver significant results and exponential growth. See the future. We transform your complex business challenges into simple profitable solutions.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.